Loading…
Loading…
VANCOUVER, BC / ACCESS Newswire / March 31, 2025 / Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") announces that on March 28, 2025, it mutually agreed with SunRegen Healthcare AG ("SunRegen") to terminate the Letter of Intent ("LOI") dated August 12, 2024, to acquire SunRegen Healthcare AG ("SunRegen"), by way of a Reverse Takeover ("RTO"). Verisante's common shares were previously halted from trading in connection with a proposed RTO with SunRegen Healthcare AG.
RTO Partner SunRegen Healthcare AG Closes Private Placement for $2.1 Million VANCOUVER, BC / ACCESSWIRE / December 18, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) ("Verisante") announces that further to its news release dated October 31, 2024, SunRegen Healthcare AG ("SunRegen") has now closed the previously announced pre-RTO private placement. As announced on August 12, 2024, Verisante entered into a binding Letter of Intent ("LOI") to acquire a 100% interest in SunRegen Healthcare AG ("SunRegen"), a Swiss pharmaceutical company.
VANCOUVER, BC / ACCESSWIRE / October 31, 2024 / Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") is pleased to announce a transaction update further to it's initial news release dated August 12, 2024, that it has entered into a binding Letter of Intent ("LOI") to acquire a 100% interest in SunRegen Healthcare AG ("SunRegen"), a Swiss pharmaceutical company. The proposed transaction is a Reverse Takeover ("RTO") pursuant to Policy 5.2 of the TSX Venture Exchange and the resulting issuer intends to qualify as a Tier 2 Life Sciences Issuer.
VANCOUVER, BC / ACCESSWIRE / August 13, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) ("Verisante") is pleased to announce that it has entered into a binding Letter of Intent ("LOI") dated August 12, 2024, to acquire a 100% interest in SunRegen Healthcare AG ("SunRegen"), a Swiss pharmaceutical company, by way of a Definitive Share Exchange Agreement which is yet to be negotiated between the parties. The proposed transaction is a Reverse Takeover ("RTO") pursuant to Policy 5.2 of the TSX Venture Exchange and the resulting issuer intends to qualify as a Tier 2 Life Sciences Issuer.
VANCOUVER, BC / ACCESSWIRE / March 30, 2024 / Verisante Technology, Inc. (TSX-V:VER.H) (the "Company") previously announced on March 14, 2024, that it had agreed to convert certain payables owed to Creditors into common shares in the capital of the Company (the "Settlement Shares"). The Company proposed to issue the Settlement Shares to preserve cash to fund future operations.
VANCOUVER, BC / ACCESSWIRE / March 14, 2024 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") is pleased to announce it has agreed to convert certain payables owed to Creditors into common shares in the capital of the Company (the "Settlement Shares"). The Company is proposing to issue the Settlement Shares in order to preserve cash to fund future operations.
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") is pleased to announce that at the 2023 Annual General Meeting held on December 18, 2023, in Vancouver, British Columbia, the Company's shareholders voted in favour of all items of business. All director nominees were elected.
VANCOUVER, BC / ACCESSWIRE / October 5, 2023 / Verisante Technology, Inc. (TSXV:VER.H) (the "Company") previously announced on September 7, 2023, that it had agreed to convert certain payables owed to Creditors into common shares in the capital of the Company (the "Settlement Shares"). The Company proposed to issue the Settlement Shares to preserve cash to fund future operations.
No recent filings indexed.